# Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

Source: https://onco.cc/trials/nct04090736/  
OnCo record `nct04090736` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pevonedistat and Azacitidine in Leukaemia, run by PETHEMA Foundation, active and no longer recruiting.

## Summary

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy is a phase 3 interventional study registered as NCT04090736 by PETHEMA Foundation, with 302 participants planned, started 2019-09-24 and due to reach its primary completion in 2023-06-30. Interventions recorded: Pevonedistat, Azacitidine. Conditions recorded: Leukemia, Myeloid, Acute.

Linked to the drug Pevonedistat because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04090736
- Phase: 3
- Setting: A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy
- Sponsor: PETHEMA Foundation
- Enrolled: 302

## Sources

- ClinicalTrials.gov NCT04090736: https://clinicaltrials.gov/study/NCT04090736

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Pevonedistat](https://onco.cc/drugs/pevonedistat/)

---
JSON: https://onco.cc/api/v1/entities/nct04090736.json